As the United Nations gears up for a high-level meeting on combating a global tuberculosis epidemic, Doctors Without Borders is urging Johnson & Johnson (JNJ) to widen access for a medicine that the advocacy group maintained is too costly for many countries.

In a Sept. 17 letter to the company, Doctors Without Borders argued that an “affordable and sustainable” supply of Sirturo is increasingly needed, especially after the World Health Organization recently recommended the drug as the backbone for treating multi-drug resistant tuberculosis.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Every entrance to a J&J building has a big copy of their vaunted Credo hanging on the wall, and their CEO’s rarely miss an opportunity to humblebrag about it. But when it comes down to it…

    • Hi Bruce,
      Yes, the credo plaque in New Brunswick is a good reference point for many discussion.
      Cheers
      ed at pharmalot

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy